Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laurus LabsBOM:540222 -0.46%66 Cyclically Adjusted PS Ratio is 18.73 as of Aug. 24, 2026, which is 66% above its 10-year median of 11.27. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹844.09 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 748 Drug Manufacturers companies, Laurus Labs ranks worse than 96.52% on this metric.
The historical rank and industry rank for Laurus Labs's Cyclically Adjusted PS Ratio or its related term are showing as below:
BOM:540222'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.9 Med: 11.27 Max: 19.29
Current: 18.74
During the past years, Laurus Labs's highest Cyclically Adjusted PS Ratio was 19.29. The lowest was 8.90. And the median was 11.27.
BOM:540222's Cyclically Adjusted PS Ratio is ranked worse than 96.52% of 748
companies
in the Drug Manufacturers industry
Industry Median: 2.045
vs BOM:540222: 18.74
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Laurus Labs's adjusted revenue per share data for the three months ended in Jun. 2026 was ₹37.483. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹96.86 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Laurus Labs (BOM:540222) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Laurus Labs Cyclically Adjusted PS Ratio Related Terms
Laurus Labs Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Laurus Labs's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540222 vs ZTS: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Laurus Labs's Cyclically Adjusted PS Ratio falls into.
Laurus Labs Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Laurus Labs's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 18.73 mean?
Laurus Labs (BOM:540222) has a Cyclically Adjusted PS Ratio of 18.73 as of Aug. 24, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Laurus Labs and its competitors. This is 66% above median its historical median of 11.27. Over the past decade, Laurus Labs' Cyclically Adjusted PS Ratio has ranged from 8.90 to 19.29. According to the industry distribution chart, Laurus Labs ranks #722 out of 748 companies in the Drug Manufacturers industry, placing it in the top 96.5%.
Is Laurus Labs' Cyclically Adjusted PS Ratio too high?
Laurus Labs' current Cyclically Adjusted PS Ratio of 18.73 is 66% above median its 10-year median of 11.27. Over the past 10 years, this metric has ranged from a low of 8.90 to a high of 19.29. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 2.05. Laurus Labs' value of 18.73 is 815.9% above this industry median. Based on the distribution chart, Laurus Labs ranks #722 out of 748 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Cyclically Adjusted PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Laurus Labs ranks #722 out of 748 companies for Cyclically Adjusted PS Ratio. This places Laurus Labs in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.05. Laurus Labs' value of 18.73 is 815.9% above this benchmark. Historically, Laurus Labs' own Cyclically Adjusted PS Ratio has ranged from 8.90 to 19.29 over the past decade. While the company's 10-year median is 11.27 vs. the industry median of 2.05, Laurus Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 2.05, based on 748 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laurus Labs's current Cyclically Adjusted PS Ratio of 18.73 is 815.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Laurus Labs and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laurus Labs's current Cyclically Adjusted PS Ratio is 18.73, which is 66% above median its own 10-year median of 11.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹844.09, compared to a current price of ₹1,814.65 — trading 115% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 18.73, which is 66% above median its 10-year median of 11.27 and 815.9% above the Drug Manufacturers industry median of 2.05. Laurus Labs' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Cyclically Adjusted PS Ratio is 18.73 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laurus Labs (BOM:540222) Overvalued in 2026?
Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued.
The current stock price of ₹1,814.65 is trading 115% above its estimated GF Value™ of ₹844.09.
GuruFocus considers Laurus Labs to be Significantly Overvalued.
Key valuation signals for BOM:540222:
Cyclically Adjusted PS Ratio: 18.73 (66% above median its 10-year median of 11.27)
GF Value™: ₹844.09 vs. price of ₹1,814.65 (115% above fair value)
Industry Position: 815.9% above the Drug Manufacturers median (#722 of 748)
No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score
Get the complete analysis for BOM:540222
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540222 has been successfully added to your 
